American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing - PubMed (original) (raw)

. 2023 Nov 28;7(22):7101-7138.

doi: 10.1182/bloodadvances.2023010177.

Robby Nieuwlaat 2 3, Lisa Baumann Kreuziger 4, Michiel Coppens 5 6, Damon Houghton 7 8, Andra H James 9, Eddy Lang 10, Stephan Moll 11, Tarra Myers 12, Meha Bhatt 2, Chatree Chai-Adisaksopha 13, Luis E Colunga-Lozano 14, Samer G Karam 2 3, Yuan Zhang 1 2, Wojtek Wiercioch 2 3, Holger J Schünemann 2 3 15, Alfonso Iorio 3

Affiliations

American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing

Saskia Middeldorp et al. Blood Adv. 2023.

Abstract

Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables. The Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE) was used. Recommendations were subject to public comment. The panel agreed on 23 recommendations regarding thrombophilia testing and associated management. Nearly all recommendations are based on very low certainty in the evidence due to modeling assumptions. The panel issued a strong recommendation against testing the general population before starting combined oral contraceptives (COCs) and conditional recommendations for thrombophilia testing in the following scenarios: (a) patients with VTE associated with nonsurgical major transient or hormonal risk factors; (b) patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophylaxis for minor provoking risk factors and for guidance to avoid COCs/hormone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for thrombophilia.

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: All authors were members of either the guideline panel or of the systematic review team. Consequently, they completed a disclosure-of-interest form, which was reviewed by ASH and is available as Supplements 2 and 3.

Figures

Figure 1.

Figure 1.

Overview of guideline questions. Minor provoking risk factors: circumstances that generally do not require prophylaxis, such as immobility or minor injury, illness, or infection. RF, risk factor.

Figure 2.

Figure 2.

Modeling approach for determining the effect of thrombophilia testing. Population considered for testing: Figure 1 with the guideline flowchart for the different populations for which a recommendation regarding thrombophilia testing was provided. Thrombophilia: any type of thrombophilia or a specific type, depending on whether the recommendation question addresses panel testing or testing for a known specific type in the family. Intervention: course of action other than “usual care.” Depending on the specific question, this means prescribing thromboprophylaxis, withholding thromboprophylaxis, extending thromboprophylaxis, stopping thromboprophylaxis, withholding COCs, or withholding HRT. Usual care: for populations where “usual care” was ambiguous, 2 scenarios were modeled, and separate recommendations were provided (see recommendations 7-10).

Comment in

Similar articles

Cited by

References

    1. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. - PMC - PubMed
    1. Institute of Medicine . National Academies Press; 2011. Clinical Practice Guidelines We Can Trust. - PubMed
    1. Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156(7):525–531. - PubMed
    1. Schunemann HJ, Al-Ansary LA, Forland F, et al. Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med. 2015;163(7):548–553. - PubMed
    1. Schunemann HJ, Wiercioch W, Etxeandia I, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ. 2014;186(3):E123–E142. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources